Bayer (BAYN) Received a €109.00 Target Price by Goldman Sachs Group Analysts

Goldman Sachs Group set a €109.00 ($126.74) price objective on Bayer (FRA:BAYN) in a research note published on Tuesday. The brokerage currently has a buy rating on the healthcare company’s stock.

Bayer AG logo

BAYN has been the topic of a number of other reports. Sanford C. Bernstein set a €115.00 ($133.72) price objective on shares of Bayer and gave the company a buy rating in a research note on Wednesday, September 5th. Cfra set a €100.00 ($116.28) price objective on shares of Bayer and gave the company a buy rating in a research note on Tuesday, August 14th. Independent Research set a €85.00 ($98.84) price objective on shares of Bayer and gave the company a neutral rating in a research note on Wednesday, September 5th. Citigroup set a €100.00 ($116.28) price objective on shares of Bayer and gave the company a buy rating in a research note on Thursday, September 20th. Finally, Commerzbank set a €111.00 ($129.07) target price on shares of Bayer and gave the stock a buy rating in a research note on Monday, August 20th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of €94.83 ($110.27).

Shares of FRA:BAYN opened at €65.42 ($76.07) on Tuesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Leveraged Buyout (LBO)

Analyst Recommendations for Bayer (FRA:BAYN)

Related posts

Leave a Comment